Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512

Figure 1

Best tumor response (waterfall plot) in evaluable patients (n = 24).

The bars on each plot represent the largest decrease under baseline of the sum of longest diameters of all target measurable lesions, or if no decrease was observed, the smallest increase in the sum of longest diameters of target measurable lesions. Patients whose best response was progression due to new lesions, death (due to disease), or clear worsening of non-measurable disease are represented by a bar showing a 100% increase. In addition, patients whose best response could not be determined due to inadequate assessment are represented on the far left side of the plot as a solid bar showing 100% increase.

Figure 1

doi: https://doi.org/10.1371/journal.pone.0048787.g001